DOCSLIB.ORG

Alexander Kutikov, MD, FACS

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Alexander Kutikov, MD, FACS CURRICULUM VITAE Alexander Kutikov, MD, FACS 333 Cottman Avenue Philadelphia, PA 19111 tel: 215.728.5342 e-mail: [email protected] CURRENT POSITION: 2017 – present Fox Chase Cancer Center Philadelphia, Pennsylvania Temple University Health System Philadelphia, Pennsylvania Chief of Urology and Urologic Oncology Professor of Urologic Oncology Department of Surgical Oncology 2013 – 2017 Fox Chase Cancer Center Philadelphia, Pennsylvania Temple University Health System Philadelphia, Pennsylvania Associate Professor of Urologic Oncology Department of Surgical Oncology 2010 – 2012 Fox Chase Cancer Center Philadelphia, Pennsylvania Assistant Professor of Urologic Oncology Department of Surgical Oncology POSTGRADUATE TRAINING: 2008 – 2010 Fox Chase Cancer Center Philadelphia, Pennsylvania Society of Urologic Oncology Fellow 2007 – 2008 University of Pennsylvania Philadelphia, Pennsylvania Chief Resident in Urology 2004 – 2007 University of Pennsylvania Philadelphia, Pennsylvania Resident in Urology 2003 – 2004 University of Pennsylvania Philadelphia, Pennsylvania Internship in General Surgery EDUCATION: 2017 – 2018 Wharton School of Business Philadelphia, PA Physician Leadership Academy 1999 – 2003 Harvard Medical School Boston, Massachusetts Doctor of Medicine, Harvard-MIT Health Sciences and Technology Program Thesis: Co-delivery of Cisplatin and Estradiol Employing a Pt(IV) Prodrug A. Kutikov Page 2 of 35 1997 – 1998 Oxford University Oxford, England Emory’s Oxford Scholar at University College Thesis: D-Block Metal Chemistry of Tricyclo[5.2.1.02,6]deca-2,5,8-triene 1995 – 1999 Emory University Atlanta, Georgia Bachelor of Science in Chemistry, Woodruff Scholar, Summa Cum Laude Thesis: Understanding the Cobalt-Carbon Bond of Vitamin B12 1991 – 1995 George Walton High School Marietta, Georgia HONORS/AWARDS: 2019 Richard E. Greenberg Resident Teaching Award, Temple Urology Residents 2019 Philadelphia Magazine Top Docs Award 2019 Castle Connolly America’s Top Doctors Award 2018 ‘Everyday Hero’ Award, Pennsylvania Medical Society A state-wide honor based on patient/peer nominations that is awarded to one physician per month in the State of Pennsylvania 2018 Aresty Scholar, Wharton School of Business In Recognition of Commitment to Lifelong Learning 2018 Castle Connolly America’s Top Doctors Award 2018 Philadelphia Magazine Top Docs Award 2017 Mid-Atlantic AUA Section Nominee for AUA’s Gold Cystoscope Award 2017 Reviewer of the Year, 2017: European Urology Journal 2017 Society of Urologic Oncology Recognition Award for Service as President of the YUO 2017 Reviewer of the Month, August 2017: European Urology Journal 2017 Castle Connolly America’s Top Doctors Award 2017 Philadelphia Magazine Top Docs Award A. Kutikov Page 3 of 35 2016 Best Poster Award in the Kidney Cancer: Localized: Surgical Therapy I Session American Urological Association Meeting, San Diego, CA 2016 Mid-Atlantic AUA Representative to the 2016 Research Forum Early Career Investigators Showcase American Urological Association Meeting, San Diego, CA 2016 BJU International Journal Innovation Award 2016 for work done on the Urology Tag Ontology Project European Association of Urology Meeting, Munich, Germany 2016 Castle Connolly America’s Top Doctors Award 2013 BJU International Journal Top Social Media Influencer in Urology 2013 Award for work done through UrologyMatch.com platform American Urological Association Meeting, San Diego, CA 2013 BJU International Journal Best Mobile App Award for drawMD Urology iPad Application American Urological Association Meeting, San Diego, CA 2011 Mid-Atlantic AUA Young Investigator Representative to the AUA’s Research Forum American Urological Association Meeting, Washington, DC 2010 American College of Surgeons Excellence in Research Award 96th Annual Clinical Congress, Surgical Forum 2009 - 2010 CaPSURE Scholar CaPSURE Scholars Program in Prostate Cancer Outcomes Research 2009 Best Poster Award in Localized Kidney Cancer for Description and Introduction of the R.E.N.A.L Nephrometry Score American Urological Association Meeting, Chicago, IL 2008 Outstanding Scholar in Urology Award Presented by Penn Urology to a graduating Chief Resident 2008 Howard M. Pollack Award Presented to the Penn resident with the top score on the in-service exam (97th percentile) 2006 1st Place for Clinical Paper, Philadelphia Urological Society Annual Residents’ Night Competition 2006 Howard M. Pollack Award Presented to the Penn resident with the top score on the in-service exam (98th percentile) 2006 Gerald P. Murphy Scholar A. Kutikov Page 4 of 35 American Urological Association / Threshold Pharmaceuticals 1999 – 2003 Prusky Scholarship, Prusky Fund for Education Merit-based scholarship in the amount of half tuition per year to a selected Harvard Medical student 1999 Summa Cum Laude, Emory University 1999 Merck Index Award, Emory University Department of Chemistry Award to the department’s top graduating senior 1999 Phi Sigma Iota Academic Honor Society, Emory University 1998 Phi Beta Kappa Academic Honor Society, Emory University 1997 – 1998 Oxford University Junior Year Abroad Scholar, Emory University The sole student selected to represent Emory College at Oxford University, England during the junior year 1996 Phi Eta Sigma Academic Honor Society, Emory University 1995 – 1999 Woodruff Scholarship, Emory University Merit-based undergraduate scholarship awarded for full tuition, room/board, and stipend 1995 STAR Scholarship, General Electric Corporation PROFESSIONAL ACTIVITIES: LOCAL/NATIONAL/INTERNATIONAL: 2013 – 2019 European Urology – Leading journal in the field of Urology (IF 14.9) Associate Editor for Digital Media 2016 – present Urologic Oncology Journal – Journal of the Society of Urologic Oncology Co-Editor of News and Topics Section 2013 – present Urology Care Foundation, American Urological Association Prostate Cancer Expert Panel 2014 – present Urology Case Reports – Elsevier Journal, Editors-in-Chief Alan Partin and Alan Wein Associate Editor 2013 – present Society of Urologic Oncology Young Urologic Oncology Steering Committee Member: 2013-2018 o President 2017-2018 A. Kutikov Page 5 of 35 o President Elect 2016-2017 o Secretary 2015-2016 Membership Committee: 2015-2016 Fellowship Committee: 2017-present Survey Committee: 2016-present 2016 – present Mid-Atlantic American Urological Association Membership Committee Member 2014 – 2016 International Russian-Speaking Urological Society Steering Committee Member 2012 – 2017 American Urological Association Consultant, Young Urologists Committee 2007 – present Philadelphia Urological Society Executive committee member and webmaster Vice President 2015 2011 – 2014 American Russian Cancer Alliance Member of the surgical and clinical advisory board 2010 – 2013 American Urological Association Consultant, Residents Committee 2007 – 2010 American College of Surgeons, Resident and Associate Society Urology Representative to the Advisory Council 2008 – 2010 American Urological Association ACS Representative to the Residents Committee FOX CHASE CANCER CENTER: 2018 – present Member, Appointments and Promotions Committee 2018 – present Physician Leader, CAUTI Prevention Committee 2017 – present Chair, Credentials Committee 2017 – present Residency Program Director for the Fox Chase Clinical Site, Temple Urology 2017 – present Residency Program Director for the Fox Chase Clinical Site, Einstein Urology A. Kutikov Page 6 of 35 2016 – present Member, Medical Staff Executive Committee 2016 – present Member, Credentials Committee 2016 – present Member, Practitioner Health Committee 2016 – 2017 Chair, Practitioner Health Committee 2012 – 2015 Cancer Genomic Institute Advisory Board Committee Member 2010 – 2015 Member, Information Technology Committee 2012 Member, Surgical Waiting Room Improvements Committee 2012 Member, CMO Selection Committee Member 2012 Member, Jeanes-FCCC Inpatient Rooms Improvements Committee 2012 – 2013 Member, US News and World Report Committee PROFESSIONAL SOCIETY MEMBERSHIP: Member, Pennsylvania Medical Society Member, American Urological Association Member, Society of Urologic Oncology Fellow, American College of Surgeons Member, Philadelphia Urological Society MEDICAL CERTIFICATION: 2012 Diplomate, American Board of Urology LICENSURE: 2003 – present Pennsylvania 2009 – present New Jersey RELATED EXPERIENCES: 2003 – 2018 Co-Founder, Co-Manager, UrologyMatch, LLC Co-founder and co-manager of the premier Internet portal for physicians and medical students. url: www.urologymatch.com Company was sold to UroToday, LLC in 2019. 2012 – 2018 Co-Founder, Co-Chief Medical Officer, Visible Health, Inc. A. Kutikov Page 7 of 35 Visible Health was formed to create mobile and web applications that help patients better understand their medical conditions and treatment options by working in direct collaboration with physicians and other care providers. The flagship product was a series of iPad applications called drawMD, which enhanced physician-patient communication by offering a new paradigm for discussion of complex medical issues. Visible Health also launched and managed a national Ureteral Stent Tracking system in collaboration with Boston Scientific. EDITORIAL REVIEW ACTIVITIES: European Urology, Associate Editor for Digital Media Urologic Oncology, Co-Editor of News and Topics Section Canadian Journal of Urology, Past Associate Editor, invited reviewer Journal of Clinical Oncology, invited reviewer Lancet, invited reviewer Cancer, invited reviewer Journal of Urology, invited reviewer
Load more

Recommended publications
  • Understanding Surgery a Guide for People with Cancer, Their Families and Friends
    Understanding Surgery A guide for people with cancer, their families and friends Treatment For information & support, call Understanding Surgery A guide for people with cancer, their families and friends First published April 2014. This edition April 2019. © Cancer Council Australia 2019. ISBN 978 1 925651 47 8 Understanding Surgery is reviewed approximately every three years. Check the publication date above to ensure this copy is up to date. Editor: Ruth Sheard. Designer: Eleonora Pelosi. Printer: SOS Print + Media Group. Acknowledgements This edition has been developed by Cancer Council NSW on behalf of all other state and territory Cancer Councils as part of a National Cancer Information Subcommittee initiative. We thank the reviewers of this booklet: Prof Andrew Spillane, Surgical Oncologist, Melanoma Institute of Australia, and Professor of Surgical Oncology, The University of Sydney Northern Clinical School, NSW; Lynne Hendrick, Consumer; Judy Holland, Physiotherapist, Calvary Mater Newcastle, NSW; Kara Hutchinson, Cancer Nurse Coordinator, St Vincent’s Hospital Melbourne, VIC; A/Prof Declan Murphy, Urologist and Director of Genitourinary Oncology, Peter MacCallum Cancer Centre, VIC; Caitriona Nienaber, 13 11 20 Consultant, Cancer Council WA; Prof Stephan Schug, Director of Pain Medicine, Royal Perth Hospital, and Chair of Anaesthesiology and Pain Medicine, The University of Western Australia Medical School, WA; Dr Emma Secomb, Specialist Surgeon, Hinterland Surgical Centre, QLD. We would like to thank the health professionals, consumers and editorial teams who have worked on previous editions of this title. This booklet is funded through the generosity of the people of Australia. Note to reader Always consult your doctor about matters that affect your health.
    [Show full text]
  • Complex General Surgical Oncology
    ACGME Program Requirements for Graduate Medical Education in Complex General Surgical Oncology ACGME-approved focused revision: February 3, 2020; effective July 1, 2020 Contents Introduction .............................................................................................................................. 3 Int.A. Preamble ................................................................................................................ 3 Int.B. Definition of Subspecialty ..................................................................................... 4 Int.C. Length of Educational Program ............................................................................ 4 I. Oversight ............................................................................................................................ 4 I.A. Sponsoring Institution............................................................................................ 4 I.B. Participating Sites .................................................................................................. 4 I.C. Recruitment ............................................................................................................. 6 I.D. Resources ............................................................................................................... 6 I.E. Other Learners and Other Care Providers ............................................................ 7 II. Personnel ...........................................................................................................................
    [Show full text]
  • Surgical Oncology 3 PGY3
    Stanford University General Surgery Residency Program Surgical Oncology 3 / Endocrine Surgery Rotation Goals and Objectives Rotation Director: Dana Lin, MD Description The Surgical Oncology 3 / Endocrine Surgery rotation offers an intensive experience in the surgical care of patients with endocrine diseases as well as breast cancer and melanoma. Goals The goal of the Surgical Oncology 3 / Endocrine Surgery rotation is to: Gain the knowledge and experience in the evaluation and management of patients with endocrine diseases, breast cancer, and melanoma. The primary goals for the R-3 resident: Develop knowledge and experience in the evaluation and management of patients with endocrine diseases, breast cancer, and melanoma. Acquire and refine procedural and operative skills required in the care of these patients. Direct the post-operative / in-patient care of the patients on the service. Objectives The Surgical Oncology 3/ Endocrine Surgery R-3 rotation has the following objectives: The resident has primary responsibility for the management of all patients admitted to or evaluated by the team in conjunction with the attending surgeon. The R-3 gains knowledge of surgical care through discussion with and teaching from the attending physicians in the inpatient and outpatient setting, attendance at the multidisciplinary endocrine tumor board conference, as well as independent reading. The resident gains operative skills through pre-operative reading and preparation and by direct intra-operative teaching and guidance from the faculty. Residents can expect frequent teaching from members of the team, both at the bedside and during formal and informal sessions. Feedback and teaching is individualized to the needs of the residents.
    [Show full text]
  • Tumor Registrar Vocabulary: the Composition of Medical Terms Book Three
    SEER Program Self InstructionalManual for Cancer Registrars Tumor Registrar Vocabulary: The Composition of Medical Terms Book Three Second Edition U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National institutesof Health SEER PROGRAM SELF-INSTRUCTIONAL MANUAL FOR CANCER REGISWRARS Book 3 - CANCER REGISTRAR VOCABULARY: THE COMPOSITION OF MEDICAL TERMS Second Edition Originally Preparedfor the Louisiana Regional Medical Program Under the Direction of: C. Dennis Fink, Ph.D., Program Director, HumRRO Robert F. Ryan, M.D., Technical Advisor, Tulane University Revised by: SEER Program Cancer Statistics Branch, National Cancer Institute Editor-in-Chief: Evelyn M. Shambaugh, M.A., CTR Cancer Statistics Branch, National Cancer Institute Assisted by Self-InstructionalManual Committee: Dr. Robert F. Ryan, EmeritusProfessor of Surgery Tulane University School of Medicine New Orleans, Louisiana Mildred Weiss Ruth Navotny Mary A. Kruse LOs Angeles, California San Francisco, California Bethesda, Maryland BOOK 3 CANCER REGISTRAR VOCABULARY: THE COMPOSITION OF MEDICAL TERMS TABLE OF CONTENTS BOOK 3: CANCER REGISTRAR VOCABULARY: THE COMPOSITION OF MEDICAL TERMS Page Section A--Objectives and Content of Book 3 ................................... 1 Section B--Word Roots, Suffixes, and Prefixes ................................... 5 Section C--Common Symptomatic Suffixes ..................................... 31 Section D--Common Diagnostic Suffixes ....................................... 63 Section E--Cancer Registrar Vocabulary: Complaints
    [Show full text]
  • Gynecologic Oncology
    GYNECOLOGIC ONCOLOGY 2018 SAUDI FELLOWSHIP GYNECOLOGIC ONCOLOGY PROGRAM SAUDI FELLOWSHIP GYNECOLOGIC-ONCOLOGY CURRICULUM PREPARATION Curriculum Scientific Group DR. HANY SALEM DR. ISMAIL ALBADAWI DR. MOHAMMAD ALSHEHRI SUPERVISION Curriculum Specialists PROF. ZUBAIR AMIN DR. SAMI ALSHAMARRI REVIEW AND APPROVAL Scientific Council DR. HANY SALEM DR. ISMAIL ALBADAWI DR. MOHAMMAD ALSHEHRI DR. MOHAMMAD ADDAR DR. ABDULAZIZ AL-OBAID SAUDI FELLOWSHIP GYNE-ONCOLOGY CURRICULUM 1 COPYRIGHTS AND AMENDMENTS All rights reserved. © 2018 Saudi Commission for Health Specialties. This material may not be reproduced, displayed, modified, distributed, or used in any other manner without prior written permission of the Saudi Commission for Health Specialties, Riyadh, Kingdom of Saudi Arabia. Any amendment to this document shall be approved by the Specialty Scientific Council and the Executive Council of the commission and shall be considered effective from the date the updated electronic version of this curriculum was published on the commission Web site, unless a different implementation date has been mentioned. Correspondence: Saudi Commission for Health Specialties P.O. Box: 94656 Postal Code: 11614 Contact Center: 920019393 E-mail: [email protected] Website: www.scfhs.org.sa Formatted and Designed by: Manoj Thomas Varghese, CMT (SCFHS) 2 SAUDI FELLOWSHIP GYNE-ONCOLOGY CURRICULUM ACKNOWLEDGEMENTS The Gynecologic Oncology Fellowship Training team acknowledges the valuable contributions and feedback from the scientific committee members in the development of this program. We extend special appreciation and gratitude to all the members who have been pivotal in the completion of this booklet, especially the Scientific Council, Curriculum Group, and the Curriculum Specialists. We would also like to acknowledge that the CanMEDS framework is a copyright of the Royal College of Physicians and Surgeons of Canada, and many of the descriptions and competencies have been acquired from their resources.
    [Show full text]
  • Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer M
    Published OnlineFirst June 13, 2017; DOI: 10.1158/1078-0432.CCR-16-3224 Personalized Medicine and Imaging Clinical Cancer Research Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer M. Eileen Dolan1, Omar El Charif1, Heather E. Wheeler2, Eric R. Gamazon3, Shirin Ardeshir-Rouhani-Fard4, Patrick Monahan4, Darren R. Feldman5, Robert J. Hamilton6, David J. Vaughn7, Clair J. Beard8, Chunkit Fung9, Jeri Kim10, Sophie D. Fossa11, Daniel L Hertz12, Taisei Mushiroda13, Michiaki Kubo13, Lawrence H. Einhorn4, Nancy J. Cox3, and Lois B. Travis4; for the Platinum Study Group Abstract Purpose: Our purpose was to characterize the clinical influ- Results: Eight sensory items formed a subscale with good ences, genetic risk factors, and gene mechanisms contributing to internal consistency (Cronbach a ¼ 0.88). Variables signifi- persistent cisplatin-induced peripheral neuropathy (CisIPN) in cantly associated with CisIPN included age at diagnosis (OR À testicular cancer survivors (TCSs). per year, 1.06; P ¼ 2 Â 10 9), smoking (OR, 1.54; P ¼ 0.004), Experimental Design: TCS given cisplatin-based therapy com- excess drinking (OR, 1.83; P ¼ 0.007), and hypertension pleted the validated EORTC QLQ-CIPN20 questionnaire. An (OR, 1.61; P ¼ 0.03). CisIPN was correlated with lower À ordinal CisIPN phenotype was derived, and associations with self-reported health (OR, 0.56; P ¼ 2.6 Â 10 9) and weight age, smoking, excess drinking, hypertension, body mass index, gain adjusted for years since treatment (OR per Dkg/m2, diabetes, hypercholesterolemia, cumulative cisplatin dose, and 1.05; P ¼ 0.004). PrediXcan identified lower expres- self-reported health were examined for 680 TCS.
    [Show full text]
  • European Society of Gynaecological Oncology Quality Indicators for Surgical Treatment of Cervical Cancer
    Original research Int J Gynecol Cancer: first published as 10.1136/ijgc-2019-000878 on 3 January 2020. Downloaded from European Society of Gynaecological Oncology quality indicators for surgical treatment of cervical cancer David Cibula,1 François Planchamp,2 Daniela Fischerova,1 Christina Fotopoulou,3 Christhardt Kohler,4 Fabio Landoni,5 Patrice Mathevet,6 Raj Naik,7 Jordi Ponce,8 Francesco Raspagliesi,9 Alexandros Rodolakis,10 Karl Tamussino,11 Cagatay Taskiran,12 Ignace Vergote,13 Pauline Wimberger,14 Ane Gerda Zahl Eriksson,15 Denis Querleu2 For numbered affiliations see ABSTRACT as a component of comprehensive multi- disciplinary end of article. Background Optimizing and ensuring the quality of management has been shown to improve outcomes 3 4 surgical care is essential to improve the management and in patients with other types of malignancies. Imple- Correspondence to outcome of patients with cervical cancer. mentation of a quality improvement program helped Dr David Cibula, Department OBJECTIVE to reduce both morbidity and costs in other tumors of Obstetrics and Gynecology, University of Prague, 110 To develop a list of quality indicators for surgical treatment where surgical interventions are also high risk. Thus, 00 Staré Město, Czechia; d_ of cervical cancer that can be used to audit and improve it is likely that implementation of a quality manage- cibula@ yahoo. com clinical practice. ment program could improve survival of patients with Methods Quality indicators were developed using a cervical cancer. four- step evaluation process that included a systematic The aim of this project was to develop a list of Received 30 August 2019 literature search to identify potential quality indicators, Revised 17 October 2019 quality indicators for surgical treatment of cervical in- person meetings of an ad hoc group of international Accepted 22 October 2019 cancer that can be used to audit and improve clin- experts, an internal validation process, and external review by a large panel of European clinicians and patient ical practice in an easy and practicable way.
    [Show full text]
  • Standards for Oncology Registry Entry STORE 2018
    STandards for Oncology Registry Entry STORE 2018 Effective for Cases Diagnosed January 1, 2018 STORE STandards for Oncology Registry Entry Released 2018 (Incorporates all updates to Commission on Cancer, National Cancer Database Data standards since FORDS was revised in 2016) Effective for cases diagnosed January 1, 2018 See Appendix A for Updates since FORDS: Revised for 2016. Version 1.0 © 2018 AMERICAN COLLEGE OF SURGEONS All Rights Reserved STORE 2018 Table of Contents Table of Contents Table of Contents ......................................................................................................................... ii Foreword ..................................................................................................................................... 1 FROM “FORDS” TO “STORE” ..................................................................................................................... 1 Preface 2018 ................................................................................................................................ 2 Comorbidities and Complications ............................................................................................................. 2 Revisions to Staging Requirements ........................................................................................................... 2 Staging Data Items No Longer Required for Cases Diagnosed in 2018 and Later (Required for Cases Diagnosed 2017 and Earlier) ................................................................................................................
    [Show full text]
  • GUIDELINES for COMPETENCY BASED POSTGRADUATE TRAINING PROGRAMME for Mch in GYNAECOLOGICAL ONCOLOGY SUBJECT SPECIFIC OBJECTIVES
    GUIDELINES FOR COMPETENCY BASED POSTGRADUATE TRAINING PROGRAMME FOR MCh IN GYNAECOLOGICAL ONCOLOGY Preamble Gynaecological Cancers (Cancer cervix, cancer uterus, tubo-ovarian cancers, vaginal and vulval cancers) comprise 25-40% of patient workload in established Departments of Radiation Oncology, Medical Oncology and Surgical Oncology. Whereas specialities such as radiation oncology and medical oncology look after all cancers, there is lack of specialists interested or devoted to the field of “Gynaecological Oncology”. A subspecialist in Gynaecological Oncology is one who has undertaken formal training in field of Gynaecological oncology and acquires special expertise in the field of Gynaecological Oncology including broad based knowledge in related disciplines such as medical oncology, radiation oncology, gynaecological pathology and palliative management of patients suffering from gynaecological cancers. SUBJECT SPECIFIC OBJECTIVES The aims of Sub-specialisation in Gynaecological Oncology are: • To create a work force of specialists trained in the field of Gynaecological Oncology. • To improve practice, knowledge and research in the field of Gynaecological Oncology. • To improve standards of care for patients suffering from gynaecological cancers. • To encourage close understanding with disciplines such as Radiation Oncology and Medical Oncology involved in the care of women suffering from gynaecological cancer. • To encourage co-ordinated management of gynaecological cancers as a multidisciplinary approach. SUBJECT SPECIFIC COMPETENCIES By the end of the course, the student should have acquired knowledge (cognitive domain), professionalism (affective domain) and skills (psychomotor domain) as per details given below: 1 A. Cognitive domain (theoretical knowledge): The post graduate student should acquire knowledge in the following areas by the end of the training programme. Thorough understanding of: .
    [Show full text]
  • Cancer Surgeries in the Time of COVID-19: a Message from the SSO President and President-Elect
    Cancer Surgeries in the Time of COVID-19: A Message from the SSO President and President-Elect March 23, 2020 Dear SSO Members, In these unprecedented times, we are forced to consider triage and rationing of cancer surgery cases. Here are a few of the reasons: • the potential shortage of supplies, such as masks, gowns, gloves • the potential shortage of hospital personnel due to sickness, quarantine and duties at home • the potential shortage of hospital beds, ICU beds and ventilators • the desire to maximize social distancing amongst our patients, colleagues and staff. We have asked each of the SSO Disease Site Work Group Chairs and Vice Chairs to provide their recommendations for managing care in their specialties, assuming a 3- to 6-month delay in care. We have summarized their recommendations below. Numerous organizations are publishing in-depth guidelines, such as the NCCN, ACS, and ASCO, and we will provide links to those documents on the SSO Website. We have also instituted a COVID-19 community discussion page in My SSO Community for members to share what is happening in their institutions. In the next few days, SSO will produce a series of podcasts featuring discussions with experts, regarding their opinions and institutional practices. These podcasts will be available on SSO’s Website, iTunes, Sticher and other podcast platforms. Please watch your email and SSO’s Twitter and Facebook pages for details. The Annals of Surgical Oncology will be publishing an editorial on this topic soon. As each institution across the world is experiencing this pandemic at different levels, the timing of rationing care will vary and must be decided locally.
    [Show full text]
  • Current Approaches to Skin Cancer Management in Organ Transplant Recipients Meena K
    Current Approaches to Skin Cancer Management in Organ Transplant Recipients Meena K. Singh, MD,* and Jerry D. Brewer, MD† Approximately 225,000 people are living with organ transplants in the United States. Organ transplant recipients have a greater risk of developing skin cancer, including basal cell carcinoma, squamous cell carcinoma, and malignant melanoma, with an approximately 250 times greater incidence of squamous cell carcinoma in certain transplant recipients, compared with the general population. Because skin cancers are the most common posttransplant malignancy, the resultant morbidity and mortality in these high-risk patients is quite significant. Semin Cutan Med Surg 30:35-47 © 2011 Elsevier Inc. All rights reserved. pproximately 225,000 people are living with organ violet B radiation induces direct DNA damage and indirectly Atransplants in the United States. Organ transplant recip- causes DNA damage through production of reactive oxygen ients (OTRs) are at increased risk for both cutaneous and species.6 UVR also promotes the development of skin cancer systemic malignancy. More than 1000 articles in the medical through cutaneous immunosuppression.7 literature discuss cancer in the setting of organ transplanta- The immunosuppressive regimen required for graft sur- tion, most of which focus on skin cancer. vival in OTRs may lead to an impaired immune surveillance Skin cancer is the most common human malignancy, with system, which may influence the development of skin can- approximately 3.5 million skin cancers diagnosed annually cers. Certain immunosuppressive agents may also promote in the United States.1 Nonmelanoma skin cancer (NMSC) is malignancy through direct carcinogenesis.8-10 Skin cancer in the most common type, with approximately 2.8 million basal the setting of organ transplantation is also influenced by hu- cell carcinomas and more than 700,000 squamous cell car- man papillomavirus carcinogenesis, cancer susceptibility cinomas (SCCs) diagnosed each year.
    [Show full text]
  • The Surgeon and the Patient with Cancer: the Development of Surgical Oncology
    Henry Ford Hospital Medical Journal Volume 30 Number 3 Article 11 9-1982 The Surgeon and the Patient with Cancer: The Development of Surgical Oncology Angelos A. Kambouris Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons Recommended Citation Kambouris, Angelos A. (1982) "The Surgeon and the Patient with Cancer: The Development of Surgical Oncology," Henry Ford Hospital Medical Journal : Vol. 30 : No. 3 , 156-159. Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol30/iss3/11 This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons. Henry Ford Hosp Med J Vol 30, No 3,1982 Sjf]iii;^c:iciiil ,iAijr'III:icic The Surgeon and the Patient with Cancer: The Development of Surgical Oncology Angelos A. Kambouris, MD* The role ofthe surgeon in treating patients with cancer to become familiar with radiotherapy, its capabilities has changed over the past 30 years. For many years the and its side effects, in order to serve the best interests of surgeon was traditionally viewed as the key clinician in their patients. Cooperative teams of surgeons and radio­ treating cancer. This role was strengthened by the therapists were established, and as the results of their development of the concept of local-regional resections combined modalities became publicized, traditional for treating cancers ofthe breast (Halsted, 1894), rectum surgical approaches were modified.
    [Show full text]